about
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patientsPredicting anthracycline benefit: have we made any progress?The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.Triple negative breast cancer: a heterogeneous subgroup defined by what it is not.Targeting triple negative breast cancer: is p53 the answer?The continued evidence from overviews: what is the clinical utility?TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream.Re-searching anthracycline therapy
P50
Q37394399-711DABA9-43E8-44AC-B9A2-E0CA1E410070Q37588442-BD05B46E-AE4E-420C-BF57-B162D548C940Q37598448-FD28D142-7A3E-4C79-9FA5-09DDF4751D39Q37937916-9DD9DF39-AD48-4BBF-A0CF-E77BD7448EB9Q38074211-271445D2-B8BF-4F16-B735-5D49C0AE2164Q38145845-65DDC34F-68F2-4C8E-A74B-4C8382D9947CQ39336778-66E7D4B4-DDB9-4282-96E8-71840E80631CQ39779772-F42CA55F-DBD1-4A4D-8EF1-92A310ACDD91Q46392491-23DA987F-8940-4193-9658-1AAD244DA670Q84408639-ABB29364-5E84-4FE3-8BC2-81609177F0DA
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Erica Moretti
@ast
Erica Moretti
@en
Erica Moretti
@es
Erica Moretti
@nl
type
label
Erica Moretti
@ast
Erica Moretti
@en
Erica Moretti
@es
Erica Moretti
@nl
prefLabel
Erica Moretti
@ast
Erica Moretti
@en
Erica Moretti
@es
Erica Moretti
@nl
P106
P1153
24724921500
P21
P31
P496
0000-0002-8114-4668